Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study

The Lancet regional health. Europe(2023)

引用 5|浏览24
暂无评分
摘要
This study did not receive funding.
更多
查看译文
关键词
COVID-19,SARS-CoV-2,Nirmatrelvir/ritonavir,Molnupiravir,Real-world,Effectiveness
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要